410 related articles for article (PubMed ID: 12393484)
1. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
Cooper LJ; Topp MS; Serrano LM; Gonzalez S; Chang WC; Naranjo A; Wright C; Popplewell L; Raubitschek A; Forman SJ; Jensen MC
Blood; 2003 Feb; 101(4):1637-44. PubMed ID: 12393484
[TBL] [Abstract][Full Text] [Related]
2. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
Serrano LM; Pfeiffer T; Olivares S; Numbenjapon T; Bennitt J; Kim D; Smith D; McNamara G; Al-Kadhimi Z; Rosenthal J; Forman SJ; Jensen MC; Cooper LJ
Blood; 2006 Apr; 107(7):2643-52. PubMed ID: 16352804
[TBL] [Abstract][Full Text] [Related]
4. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Jensen MC; Popplewell L; Cooper LJ; DiGiusto D; Kalos M; Ostberg JR; Forman SJ
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1245-56. PubMed ID: 20304086
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor.
Laurin D; Marin V; Biagi E; Pizzitola I; Agostoni V; Gallot G; Vié H; Jacob MC; Chaperot L; Aspord C; Plumas J
J Immunother; 2013 Apr; 36(3):181-9. PubMed ID: 23502765
[TBL] [Abstract][Full Text] [Related]
6. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
Micklethwaite KP; Savoldo B; Hanley PJ; Leen AM; Demmler-Harrison GJ; Cooper LJ; Liu H; Gee AP; Shpall EJ; Rooney CM; Heslop HE; Brenner MK; Bollard CM; Dotti G
Blood; 2010 Apr; 115(13):2695-703. PubMed ID: 20110422
[TBL] [Abstract][Full Text] [Related]
7. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
Davies JK; Singh H; Huls H; Yuk D; Lee DA; Kebriaei P; Champlin RE; Nadler LM; Guinan EC; Cooper LJ
Cancer Res; 2010 May; 70(10):3915-24. PubMed ID: 20424114
[TBL] [Abstract][Full Text] [Related]
8. The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia.
Matsumoto K; Anasetti C
Leuk Lymphoma; 1999 Nov; 35(5-6):427-35. PubMed ID: 10609780
[TBL] [Abstract][Full Text] [Related]
9. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
Terakura S; Yamamoto TN; Gardner RA; Turtle CJ; Jensen MC; Riddell SR
Blood; 2012 Jan; 119(1):72-82. PubMed ID: 22031866
[TBL] [Abstract][Full Text] [Related]
10. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
11. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
[TBL] [Abstract][Full Text] [Related]
13. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
14. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
[TBL] [Abstract][Full Text] [Related]
15. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes.
de Waal Malefyt R; Verma S; Bejarano MT; Ranes-Goldberg M; Hill M; Spits H
Eur J Immunol; 1993 Feb; 23(2):418-24. PubMed ID: 7679643
[TBL] [Abstract][Full Text] [Related]
16. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Daniyan AF; Brentjens RJ
J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
[TBL] [Abstract][Full Text] [Related]
17. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
18. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
19. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
[TBL] [Abstract][Full Text] [Related]
20. Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation.
Van de Wiel-van Kemenade E; Te Velde AA; De Boer AJ; Weening RS; Fischer A; Borst J; Melief CJ; Figdor CG
Eur J Immunol; 1992 Jun; 22(6):1467-75. PubMed ID: 1376259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
